Edwards will report directly to bioAffinity Technologies President and CEO Maria Zannes. "We are delighted to welcome Michael ...

More doctors are ordering bioAffinity Technologies' CyPath Lung test and sales are skyrocketing. A long-term military health ...

Affinity Technologies has appointed J. Michael Edwards as Chief Financial Officer. Takeaway Points bioAffinity Technologies ...

Affinity Technologies' CyPath® Lung test will be added to the Federal Supply Schedule to help veterans and active military at ...

Affinity Technologies today announced it appointed J. Michael Edwards as chief financial officer in September.

SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer ...

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that J. Michael ...

SAN ANTONIO - bioAffinity Technologies, Inc. (NASDAQ:BIAF; BIAFW), a biotech firm engaged in developing noninvasive tests for early-stage cancer detection, has appointed J. Michael Edwards as its ...

SAN ANTONIO - bioAffinity Technologies, Inc. (NASDAQ:BIAF; BIAFW), a biotech firm engaged in developing noninvasive tests for early-stage cancer detection, has appointed J. Michael Edwards as its ...

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that J. Michael Edwards ...

CyPath Lung is a laboratory-developed assay that uses self-collected sputum samples treated with a fluorescent compound that preferentially binds to cancer cells and cancer-related cells, San ...